Summary
Pharmacoeconomic evaluations estimate the value of medical interventions by comparing their clinical consequences and costs. Economic analyses, based on resource use data collected during 3 clinical trials of lenograstim, were performed as part of a lenograstim economic evaluation programme.
Undertaking economic evaluations alongside clinical trials presents a number of methodological challenges, since the trials may be performed in atypical settings, have inappropriate follow-up, or use end-points that are not useful for economic evaluation.
This paper reports on how these challenges were met in the lenograstim economic evaluation programme. In particular, it was decided that the evaluations would be based on an intent-to-treat perspective, with the same period of follow-up (for costs) for both lenograstim and vehicle groups.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anonymous. Guidelines for the submission of data to the Pharmaceutical Benefits Advisory Committee (PBAC) including economic analysis. Commonwealth of Australia, Canberra: 1992
Drummond MF. Cost-effectiveness guidelines for reimbursement of Pharmaceuticals: is economic evaluation ready for its enhanced status? Health Economics 1992; 1: 85–92
Drummond MF, Rutten FFH, Brenna A, et al. Economic evaluation of pharmaceuticals: a European perspective. Pharmacoeconomics 1993; 4: 173–86
Drummond MF, Davies LM. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991; 7: 561–73
Chevallier B, Chollet P, Merrouche Y, et al. Glycosylated rHuG-CSF (lenograstim) prevents morbidity from FEC-HD chemotherapy in inflammatory breast cancer (IBC). Proc Am Soc Clin Oncol 1993; 12: 137
Gisselbrecht C, Lepage E, Haioun C, et al. Lenograstim (glycosylated recombinant human G-CSF) supported chemotherapy optimisation in aggressive nonHodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol 1993; 12: 363
Woll PS, Hodgketts H, Lomax L, et al. Use of rHuG-CSF (lenograstim) to dose intensify in small cell lung cancer (SCLC): a randomised study. Eur J Cancer 1993; 29A Suppl. 6: S154
Drummond MF, Bloom BS, Carrin G, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess HealthCare 1992; 8: 671–82
Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38–42
Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990; 301: 309–14
Revicki D, Luce B, Weschler JM, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990; 41: 850–4
Frank RG. Clozapine’s cost-benefits. Correspondence. Hosp Community Psychiatry 1991; 42: 92
Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony —stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–70
O’Brien B, Drummond MF, Labelle R, et al. In search of power and significance: issues in the design and analysis of stochastic economic appraisals. Med Care 1994; 32: 150–63
Drummond MF, O’Brien B. Clinical importance, statistical significance and the assessment of economic and quality-of-life outcomes. Health Economics 1993; 2: 205–12
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Drummond, M., Menzin, J. & Oster, G. Methodological Issues in Economic Assessments of New Therapies. Pharmacoeconomics 6 (Suppl 2), 18–26 (1994). https://doi.org/10.2165/00019053-199400062-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199400062-00005